This company has been marked as potentially delisted and may not be actively trading. NASDAQ:PGNX Progenics Pharmaceuticals (PGNX) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Progenics Pharmaceuticals Stock (NASDAQ:PGNX) 30 days 90 days 365 days Advanced Chart Get PGNX alerts:Sign Up Key Stats Today's Range$3.94▼$4.7950-Day Range$4.10▼$4.1052-Week Range$1.89▼$6.37Volume34.93 million shsAverage Volume1.16 million shsMarket Capitalization$355.05 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Progenics Pharmaceuticals, Inc., an oncology company, develops, manufactures, and commercializes pharmaceutical products and other technologies to target, diagnose, and treat cancer cancer in the United States and internationally. The company's product candidates include Azedra, a radiotherapeutic product candidate for the treatment of iobenguane scan positive, unresectable, and locally advanced or metastatic pheochromocytoma or paraganglioma for adult and pediatric patients; PyL, a clinical-stage fluorinated prostate specific membrane antigen (PSMA)-targeted PET/CT imaging agent for prostate cancer; and 1095, a PSMA-targeted Iodine-131 labeled small molecule, which is in Phase II clinical trial for the treatment of metastatic castration-resistant prostate cancer. Its product candidates also comprise PSMA TTC, a thorium-227 labeled PSMA-targeted antibody therapeutic that is in Phase I clinical trial for treatment of metastatic prostate cancer; and Leronlimab, a humanized monoclonal antibody, which is in Phase III development for the treatment of HIV infection. The company also offers Relistor-subcutaneous injection for the treatment of opioid-induced constipation (OIC) in adults with chronic non-cancer pain or advanced-illness adult patients; Relistor tablets for the treatment of OIC in adults with chronic non-cancer pain; PSMA AI, an imaging analysis technology that uses artificial intelligence and machine learning to quantify and automate the reading of PSMA targeted imaging; and automated bone scan index, a software that quantifies the hotspots on bone scans and calculates the bone scan index value. It has license agreement with Salix Pharmaceuticals, Inc. for the development and commercialization of Relistor worldwide; and Amgen Fremont, Inc. to use its XenoMouse technology for generating human antibodies to PSMA. Progenics Pharmaceuticals, Inc. was founded in 1986 and is based in New York City, New York. Read More Receive PGNX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Progenics Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address PGNX Stock News HeadlinesPGNX_old Historical DataOctober 28, 2023 | investing.comInvesting in Pharmaceutical StocksMarch 3, 2023 | fool.comYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what the Department of Justice just admitted in court—claiming cash isn't legally your property. What does that mean? It means Washington thinks they can seize, freeze, or drain your accounts—whenever they want.July 8 at 2:00 AM | Priority Gold (Ad)Deciphera Pharmaceuticals Stock (NASDAQ:DCPH), Quotes and News SummaryFebruary 24, 2023 | benzinga.comOpioid Induced Constipation (OIC) Drug Market Size in 2023 | NEWEST REPORT | Touch New Level in Forthcoming year till 2028February 13, 2023 | marketwatch.comInsights on the Flexible Manufacturing Systems for Pharmaceutical Industry Global Market to 2031 - by Product Type, Technology, End-user and RegionFebruary 11, 2023 | finance.yahoo.comI've Got an Options Bandage for a Sick EconomyJune 19, 2022 | realmoney.thestreet.comDow Closes at Record High for 7th Straight Session as Microsoft SurgesJanuary 21, 2022 | thestreet.comSee More Headlines PGNX Stock Analysis - Frequently Asked Questions How were Progenics Pharmaceuticals' earnings last quarter? Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) announced its quarterly earnings results on Thursday, May, 7th. The biotechnology company reported ($0.19) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.22) by $0.03. The biotechnology company had revenue of $6.25 million for the quarter. Progenics Pharmaceuticals had a negative net margin of 180.28% and a negative trailing twelve-month return on equity of 129.46%. What other stocks do shareholders of Progenics Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Progenics Pharmaceuticals investors own include Synergy Pharmaceuticals (SGYP), Caterpillar (CAT), Exelixis (EXEL), IMAX (IMAX), Bristol Myers Squibb (BMY), Novavax (NVAX) and Citius Pharmaceuticals (CTXR). Company Calendar Last Earnings5/07/2020Today7/08/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:PGNX CIK835887 Webwww.progenics.com Phone646-975-2500FaxN/AEmployees79Year FoundedN/AProfitability EPS (Trailing Twelve Months)($0.80) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$68.55 million Net Margins-180.28% Pretax MarginN/A Return on Equity-129.46% Return on Assets-53.23% Debt Debt-to-Equity Ratio0.99 Current Ratio2.12 Quick Ratio2.12 Sales & Book Value Annual Sales$34.99 million Price / Sales10.15 Cash FlowN/A Price / Cash FlowN/A Book Value$0.54 per share Price / Book7.59Miscellaneous Outstanding Shares86,597,000Free FloatN/AMarket Cap$355.05 million OptionableOptionable Beta1.89 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report This page (NASDAQ:PGNX) was last updated on 7/8/2025 by MarketBeat.com Staff From Our PartnersThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredF1 Engineering Powers This Electric Marine MotorThe future of marine propulsion has arrived - powered by F-1 grade engineering. In collaboration with McLar...The Tomorrow Investor | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredNobel Prize Material Finally Goes CommercialA Nobel Prize–winning material just got its biggest breakthrough in 30 years. A little-known company has cr...True Market Insiders | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Progenics Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Progenics Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.